# A Study of Anti-PD-L1 Antibody ZKAB001 Combined With Albumin-bound Paclitaxel in Advanced Urothelial Carcinoma

> **NCT04603846** · PHASE1 · UNKNOWN · sponsor: **Lee's Pharmaceutical Limited** · enrollment: 20 (estimated)

## Conditions studied

- Advanced Urothelial Carcinoma

## Interventions

- **DRUG:** anti-PD-L1 antibody
- **DRUG:** albumin bound paclitaxel

## Key facts

- **NCT ID:** NCT04603846
- **Lead sponsor:** Lee's Pharmaceutical Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09-10
- **Primary completion:** 2022-10-01
- **Final completion:** 2023-08-25
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2022-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04603846

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04603846, "A Study of Anti-PD-L1 Antibody ZKAB001 Combined With Albumin-bound Paclitaxel in Advanced Urothelial Carcinoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04603846. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*